Stocktoria
Innoviva, Inc. INVA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-10-05
Innoviva, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 74.8% | 82.6% | 79.2% | — | — |
| Operating margin | 39.8% | 46.5% | 36.7% | — | 95.7% |
| FCF margin | 47.6% | 52.5% | 45.3% | 60.9% | 92.8% |
| Debt / equity | 0.22× | 0.37× | 0.66× | 0.79× | 0.75× |
| Current ratio | 14.64 | 2.35 | 9.03 | 3.29 | 54.02 |
| Revenue growth | 14.7% | 15.5% | -6.3% | -15.4% | 16.4% |
Source: SEC EDGAR filings · CIK 0001080014 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.